Get startedLog in
    Picture of Emcure Pharmaceuticals logo

    EMCURE — Emcure Pharmaceuticals Cashflow Statement

    0.000.00%
    in flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Emcure Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    2026
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSPROSPECTUSARSPRESS
    Standards:
    IAS
    IAS
    IAS
    IAS    		—
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line9,7257,4727,2729,71312,871
    Depreciation
    Non-Cash Items1,5392,3222,3071,6741,396
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-3,890-4,927-1,731-6,712-8,982
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities9,8237,46910,9728,5179,435
    Capital Expenditures-3,970-4,034-3,071-4,069-5,477
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-3,918-643-4,0543,129-6,454
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-7,888-4,677-7,125-940-11,931
    Financing Cash Flow Items-2,178-2,229-2,706-1,287-948
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-1,519-1,454-1,642-8,1403,434
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash4191,3362,185-5831,121